Generic drug: procarbazine hydrochloride
Brand name: Matulane
What is Matulane (procarbazine hydrochloride), and how does it work?
What are the side effects of Matulane?
It is recommended that Matulane be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.
Common side effects of Matulane include:
- nausea and vomiting (may be severe),
- loss of appetite,
- stomach pain,
- dry mouth,
- difficulty swallowing,
- trouble sleeping,
- muscle or joint pain,
- temporary hair loss,
- darkening of the skin,
- itching or rash,
- urinating more than usual, or
- changes in your menstrual periods
What is the dosage for Matulane?
- The following doses are for administration of the drug as a single agent.
- When used in combination with other anticancer drugs, the Matulane dose should be appropriately reduced, eg, in the MOPP regimen, the Matulane dose is 100 mg/m² daily for 14 days.
- All dosages are based on the patient's actual weight.
- However, the estimated lean body mass (dry weight) is used if the patient is obese or if there has been a spurious weight gain due to edema, ascites or other forms of abnormal fluid retention.
- To minimize the nausea and vomiting experienced by a high percentage of patients beginning Matulane therapy, single or divided doses of 2 to 4 mg/kg/day for the first week are recommended.
- Daily dosage should then be maintained at 4 to 6 mg/kg/day until maximum response is obtained or until the white blood count falls below 4000/cmm or the platelets fall below 100,000/ cmm.
- When maximum response is obtained, the dose may be maintained at 1 to 2 mg/kg/day.
- Upon evidence of hematologic or other toxicity, the drug should be discontinued until there has been satisfactory recovery.
- After toxic side effects have subsided, therapy may then be resumed at the discretion of the physician, based on clinical evaluation and appropriate laboratory studies, at a dosage of 1 to 2 mg/kg/day.
- Very close clinical monitoring is mandatory. Undue toxicity, evidenced by tremors, coma and convulsions, has occurred in a few cases. Dosage, therefore, should be individualized. The following dosage schedule is provided as a guideline only.
- Fifty (50) mg per square meter of body surface per day is recommended for the first week.
- Dosage should then be maintained at 100 mg per square meter of body surface per day until maximum response is obtained or until leukopenia or thrombocytopenia occurs.
- When maximum response is attained, the dose may be maintained at 50 mg per square meter of body surface per day.
- Upon evidence of hematologic or other toxicity, the drug should be discontinued until there has been satisfactory recovery, based on clinical evaluation and appropriate laboratory tests.
- After toxic side effects have subsided, therapy may then be resumed.
- Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
What drugs interact with Matulane?
Is Matulane safe to use while pregnant or breastfeeding?
- It is not known whether Matulane is excreted in human milk.
- Because of the potential for tumorigenicity shown for procarbazine hydrochloride in animal studies, mothers should not nurse while receiving this drug.
- Procarbazine hydrochloride can cause fetal harm when administered to a pregnant woman.
- While there are no adequate and well-controlled studies with procarbazine hydrochloride in pregnant women, there are case reports of malformations in the offspring of women who were exposed to procarbazine hydrochloride in combination with other antineoplastic agents during pregnancy.
- Matulane should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
- Women of childbearing potential should be advised to avoid becoming pregnant.
Matulane (procarbazine hydrochloride) Capsules is a cancer medication that is given with other cancer medications to treat Hodgkin's Disease (a type of blood cancer). Common side effects of Matulane include nausea and vomiting (may be severe), loss of appetite, stomach pain, constipation, dry mouth, diarrhea, difficulty swallowing, drowsiness, tiredness, dizziness, headache, trouble sleeping, muscle or joint pain, temporary hair loss, darkening of the skin, itching or rash, urinating more than usual, or changes in your menstrual periods.
Multimedia: Slideshows, Images & Quizzes
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Blood Cancer Types: Leukemia, Lymphomas, Myelomas, and More
Types of blood cancers include leukemia, lymphomas, multiple myelomas, and others discussed in this slideshow. Symptoms may...
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
Related Disease Conditions
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice, it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
What Is the Life Expectancy of a Person With Leukemia?
Leukemia is a group of cancers of the blood affecting the white blood cells. White blood cells are the infection-fighting cells of the body. In adults, leukemia is most common in people older than 55 years, with the average age of diagnosis being 66 years. It is also one of the most common cancers in children and adults younger than 20 years. The survival rate is higher for younger people.
How Does Leukemia Kill?
Leukemia is a cancer of the white blood cells of the bone marrow. Patients with leukemia have an over-production of a particular blood cell type in the body, the white blood cells (cells that fight infection, and provide immunity).
What Is Non-Hodgkin's Lymphoma?
Non-Hodgkin's lymphoma (NHL) is cancer of the lymphatic system, a vital part of the body's immune system. Symptoms include swollen lymph nodes, fever, night sweats, coughing, weakness, chest pain, unexplained weight loss, and abdominal pain.
Can Lymphoma Be Completely Cured?
Lymphomas are considered to be a treatable form of cancer if detected early. The overall 5-year survival rate for non-Hodgkin lymphoma (NHL) is 62%, whereas the 5-year survival rate for Hodgkin lymphoma is 92% if detected early.
What Is Burkitt Lymphoma?
There are multiple types of Burkitt lymphoma. Burkitt lymphomas are types of non-Hodgkin's lymphoma that affect the bone marrow and central nervous system. Symptoms of Burkitt lymphoma may include nausea, vomiting, headache, fatigue, enlarged lymph nodes, and many other symptoms. Diagnosis involves lab testing, imaging studies, patient history, and cytogenic evaluation. There are multiple staging systems used to stage Burkitt lymphoma. Treatment consists of chemotherapy. The prognosis tends to be more favorable in children than in adults.
Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma. It is not known what causes MCL. MCL signs and symptoms include fever, enlarged spleen and liver, fatigue, and weight loss. Treatment of MCL incorporates radiotherapy and chemotherapy. MCL has a poor prognosis as it typically is diagnosed in a late stage.
Survival Rate for Acute Lymphoblastic Leukemia
The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient. Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.
Hodgkin's vs. Non-Hodgkin's Lymphoma
Both Hodgkin's disease (sometimes referred to as Hodgkin's lymphoma) and non-Hodgkin's lymphoma are cancers that originate in a type of white blood cell known as a lymphocyte, an important component of the body's immune system.
What Is the Main Cause of Primary Lymphoma of Bone?
Primary lymphoma of bone (PLB) is a rare type of cancer that starts in the bone instead of the lymph nodes. PLB accounts for less than 5% of all bone tumors. PLB is also known as reticulum cell sarcoma, malignant lymphoma of bone or osteolymphoma, and it is a type of non-Hodgkin’s lymphoma. Pain is the most common symptom of PLB.
How Bad Is Lymphoma Cancer Of Bone?
Lymphoma is a cancer of infection-fighting cells (lymphocytes), white blood cells of the immune system. These cells are normally found in the lymph nodes, spleen, thymus, and bone marrow.
Leukemia: Signs, Symptoms, And Complications
Leukemia results when the genetic material (DNA) of a single cell in the bone marrow transforms, this is called a mutation. A mutated cell does not perform body function, but it eats away the nutrition meant for the normal cells.
How Do You Get Non-Hodgkin’s Lymphoma?
Non-Hodgkin lymphoma (NHL) is cancer that affects the lymphatic system, a part of the body’s immune system. The lymphatic system helps in filtering foreign cells and microorganisms. The lymphatic system is comprised of lymph fluid, lymph nodes, tonsils, thymus, and the spleen.
What Are the Stages of Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia is a cancer of the blood and bone marrow. With this type of cancer, the marrow creates too many abnormal lymphocytes. There are five stages of chronic lymphocytic leukemia.
Treatment & Diagnosis
- Leukemia FAQs
- Actor Michael C. Hall's Successful Treatment of Hodgkin's Disease
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL)
- Is Multiple Myeloma the Same as Leukemia?
- Does Folic Acid Prevent Leukemia?
- Can Folic Acid Prevent Leukemia?
- Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
- The Predicted 'Tripledemic' Is Here: Why Isn't There an RSV Vaccine?
- Frozen Stuffed Chicken Products & Microwave Ovens: A Recipe for Salmonella
- First FDA-Approved Fecal-Based Treatment Helps Fight a Tough Superbug
- Seizures Seem Tied to Faster Decline in People With Dementia
- Signs That COVID Infection Might Harm the Liver
- More Health News »
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.